Afatinib (Gilotrif®®, Giotrif®®, Afanix®®), an oral irreversible inhibitor of the ERBB family originally approved for EGFR-altered NSCLC patients, was studied in a Phase II trial (NCT02122172) in platinum-refractory mUC and demonstrated some efficacy in PFS at 3 months, with five of the six patients with HER2 and ERBB3 alterations meeting the endpoint [50]. Here, EGFR is linked to non-small cell lung carcinoma.